Synthetic antibodies targeting EphA2 induce diverse signaling‐competent clusters with differential activation
Protein Science · 2025-06 · 34 (6)
DOI: 10.1002/pro.70145 ↗At a glance
Journal article in Protein Science, published online on 2025-05-24. Written by Jarrett J Adams and 8 co-authors. Institution: School of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada. Major MEDLINE topics: Receptor, EphA2, Signal Transduction. Cited 1 times so far (Crossref); 64 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ontario Ministry of Research and Innovation, CIHR, Rivkin Center for Ovarian Cancer.
Abstract (original language)
The receptor tyrosine kinase EphA2 interacts with ephrin (Efn) ligands to mediate bi‐directional signals that drive cellular sorting processes during tissue development. In the context of various cancers, EphA2 can also drive invasive metastatic disease and represents an important target for cancer therapeutics. Natural Efn ligands sterically seed intertwined EphA2 clusters capable of recruiting intracellular kinases to mediate trans‐phosphorylation. Synthetic proteins, such as antibodies (Abs), can mimic Efn ligands to trigger EphA2 signaling, leading to receptor internalization and degradation, and enabling intracellular delivery of conjugated drugs. Furthermore, Abs are capable of recruiting EphA2 into clusters distinct from those seeded by Efn. We developed three synthetic Abs targeting distinct EphA2 domains and determined the paratope valency necessary for agonist or antagonist properties of each of the three epitopes. Structural modeling of monovalent Fabs in complex with EphA2 elucidated competitive and non‐competitive mechanisms of inhibition of EphA2 canonical signaling. Likewise, modeling of clusters induced by bivalent IgGs elucidated multiple signaling‐competent EphA2 clusters capable of triggering a continuum of signaling strengths and provided insights into the requirement for multimerization of EphA2 to trigger phosphorylation. Our study shows how different agonist clusters lead to distinct kinase recruitment efficiencies to modify phosphotyrosine signal strength, and provides a panel of anti‐EphA2 Abs as reagents for the development of therapeutics.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.
ORCID profiles: Jarrett J Adams
Funding
- Ontario Ministry of Research and Innovation
- CIHR
- Rivkin Center for Ovarian Cancer
- Canada Foundation for Innovation
- Genome Canada
- Canadian Institutes of Health Research
Cite
APA
Adams, J. J., Bruce, H. A., Subramania, S., Ploder, L., Garcia, J., Pot, I., Blazer, L. L., Singer, A. U., & Sidhu, S. S. (2025). Synthetic antibodies targeting EphA2 induce diverse signaling‐competent clusters with differential activation. Protein Science, 34(6). https://doi.org/10.1002/pro.70145
Vancouver
Adams JJ, Bruce HA, Subramania S, Ploder L, Garcia J, Pot I, et al. Synthetic antibodies targeting EphA2 induce diverse signaling‐competent clusters with differential activation. Protein Science. 2025;34(6). doi:10.1002/pro.70145
BibTeX
@article{Adams2025,
author = {Adams, Jarrett J and Bruce, Heather A and Subramania, Suryasree and Ploder, Lynda and Garcia, Julia and Pot, Isabelle and Blazer, Levi L and Singer, Alexander U and Sidhu, Sachdev S},
title = {Synthetic antibodies targeting EphA2 induce diverse signaling‐competent clusters with differential activation},
journal = {Protein Science},
year = {2025},
volume = {34},
number = {6},
doi = {10.1002/pro.70145}
}
EUVIMED